analyst breaks down what is behind eli lilly's q3 earnings miss
Published 3 years ago • 122 plays • Length 1:59
Download video MP4
Download video MP3
Similar videos
-
4:39
eli lilly ceo reacts to q3 earnings miss, provides pipeline update
-
1:54
eli lilly blows past estimates, hikes guidance as zepbound, mounjaro sales soar
-
8:11
eli lilly ceo david ricks on q3 earnings beat, mounjaro strength
-
6:05
eli lilly ceo david ricks on q2 results: seeing unbelievable demand for zepbound and mounjaro
-
3:58
eli lilly hits record high: here's what investors need to know
-
15:14
what i eat to lose weight! mounjaro weight loss | zepbound weight loss -85lbs down
-
2:12
lilly's weight-loss shot zepbound cuts diabetes risk, study says
-
5:32
these are the stocks to buy for the next 10 years
-
3:45
novo nordisk, eli lilly have strong first-mover advantage: analyst
-
4:19
eli lilly is a 'great destination for investors', says deutsche bank's james shin after upgrade
-
5:33
eli lilly ceo david ricks on 3-year obesity drug study: this is a profound result
-
2:49
eli lilly and novo nordisk are ahead in manufacturing but need time to meet demand, says louise chen
-
6:43
eli lilly ceo on weight loss drugs outlook: our top priority is making more product
-
5:01
eli lilly ceo weighs in on q4 revenue miss
-
4:57
health care bucks sell-off as eli lilly soars: mizuho's jared holz on what's next for the group
-
4:29
eli lilly ceo david ricks breaks down q1 earnings, obesity drug trial results
-
0:59
eli lilly ceo on why food companies haven't seen a big impact on sales
-
1:57
eli lilly posts weaker-than-expected q3 earnings
-
1:38
chart of the day: eli lilly
-
6:11
leerink's david risinger talks eli lilly seeing best trading day in a year after earnings
-
3:00
eli lilly is becoming the 'goat' of obesity, says bmo's evan seigerman
-
4:22
fda approves a new alzheimer's drug from eli lilly
Clip.africa.com - Privacy-policy